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We have shown that mitochondrial DNA-depleted (0)
SK-Hep1 hepatoma cells are resistant to apoptosis, con-
trary to previous papers reporting normal apoptotic
susceptibility of 0 cells. We studied the changes of gene
expression in SK-Hep1 0 cells. DNA chip analysis
showed that MnSOD expression was profoundly in-
creased in 0 cells. O2
. contents increased during 0 cell
derivation but became normalized after establishment
of 0 phenotypes, suggesting that MnSOD induction is
an adaptive process to increased O2
.. 0 cells were resist-
ant to menadione, paraquat, or doxorubicin, and O2
. con-
tents after treatment with them were lower in 0 cells
compared with parental cells because of MnSOD over-
expression. Expression levels and activity of glutathione
peroxidases were also increased in 0 cells, rendering
them resistant to exogenous H2O2. 
0 cells were resistant
to p53, and intracellular ROS contents after p53 expres-
sion were lower compared with parental cells. Other
types of 0 cells also showed increased MnSOD expres-
sion and resistance against ROS. Heme oxygenase-1 ex-
pression was increased in 0 cells, and a heme oxygen-
ase-1 inhibitor decreased the induction of MnSOD in 0
cells and their resistance against ROS donors. These
results indicate that 0 cells are resistant to cell death
contrary to previous reports and suggest that an adapt-
ive increase in the expression of antioxidant enzymes
renders cancer cells or aged cells with frequent mito-
chondrial DNA mutations to resist against oxidative
stress, host anti-cancer surveillance, or chemotherapeu-
tic agents, conferring survival advantage on them.
Since the first report of mitochondrial DNA (mtDNA)1-de-
pleted mammalian cells, a number of mtDNA-depleted cells (0
cells) have been produced by long-term treatment of cells with
ethidium bromide (EtBr) or other reagents that inhibit repli-
cation of mitochondrial genes (1). Such cells and their cybrids
provided valuable cell models for studying important functions
of mitochondria such as oxidative phosphorylation, ATP pro-
duction, electron transport, and reactive oxygen species (ROS)
generation. In addition to such well known functions, recent
investigations revealed that mitochondria are the master play-
ers in both apoptosis and necrosis, two classical modes of cell
death (2, 3).
Because of the essential role of mitochondria in cell death, 0
cells could be employed as important tools for the study of cell
death. However, most 0 cells have been reported to undergo
apoptosis as efficiently as their parental cells (4–6). In con-
trast, we have reported that mtDNA-depleted hepatoma cells
(SK-Hep1 0 cells) are resistant to TRAIL-induced apoptosis,
which is consistent with the importance of mitochondria in cell
death (7). However, it is not clearly elucidated how those cells
with mitochondrial dysfunction resist cell death. It is even not
well understood how such cells with defective oxidative phos-
phorylation survive.
We studied the changes of the gene expression profile in
SK-Hep1 0 cells that allow them to survive in the absence of
oxidative phosphorylation and to resist against apoptotic stim-
uli. We observed that manganese superoxide dismutase (Mn-
SOD) and other antioxidant enzymes such as glutathione per-
oxidases (GPx) are up-regulated in those cells leading to an
efficient disposal of increased oxidative stress and increased
resistance against ROS or p53, which might be related to the
resistance of cancer cells (8, 9) or aged cells (10, 11) with
mtDNA mutations against apoptosis and their avoidance of the
host surveillance. Our results indicate that 0 cells are resist-
ant to various forms of cell death contrary to previous reports
and that intact mitochondrial function is crucial for the execu-
tion of cell death.
EXPERIMENTAL PROCEDURES
MtDNA-depleted 0 Cells—SK-Hep1 0 cells were derived from
SK-Hep1 hepatoma cells by culturing in the presence of 100 ng/ml
EtBr for more than 20 generations (7, 12). MIN6N8 0 cells were
developed by treating MIN6N8 murine insulinoma cells (13) with
EtBr for more than 20 generations. PCR analysis using primers
specific for human or murine mtDNA, measurement of cytochrome c
oxidase activity and ATP contents all indicated that SK-Hep1 0 cells
(12) and MIN6N8 0 cells are authentic 0 cells. MDA-MB-435 0 cells
of a breast cancer cell origin were derived by essentially the same
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method (14). All 0 cells were maintained in the presence of 50 g/ml
uridine.
RT-PCR—Total RNA was extracted from parental cells and SK-Hep1
0 cells by using TRIzol reagent (Invitrogen). Total RNA was digested
by RNase-free DNase I treatment for 20 min, extracted using phenol-
chloroform, and then precipitated with 2.5 volumes of 100% ethanol.
Reverse transcription was carried out using Superscript II (Invitrogen)
and oligo(dT)12–18 primer. PCR amplification using primer sets specific
for each target gene was carried out at 59 °C annealing temperature for
25 cycles. Nucleotide sequences of the primers were based on published
cDNA sequences (MnSOD forward, GGTAGCACCAGCACTAGCAG;
MnSOD reverse, GTGCAGTACTCTATACCACTACA; copper,zinc
superoxide dismutase (Cu,Zn-SOD) forward, CAGTGCAGGTCCTCAC-
TTTA; Cu,Zn-SOD reverse, CCTGTCTTTGTACTTTCTTC; classical
GPx (cGPx) forward, AAGGTACTACTTATCGAGAATGTG; cGPx re-
verse, GTCAGGCTCGATGTCAATGGTCTG; phospholipid hyd-
roperoxide GPx (PHGPx) forward, TGTGCGCGCTCCATGCACGAGT;
PHGPx reverse, AAATAGTGGGGCAGGTCCTTCTCT; catalase forwa-
rd, TTAATCCATTCGATCTCACC; catalase reverse, GGCGGTGAGTG-
TCAGGATAG; glyceraldehyde-3-phosphate dehydrogenase forward,
ACCCAGAAGACTGTGGATGG; glyceraldehyde-3-phosphate dehydro-
genase reverse, TTCTAGACGGCAGGTCAGGT); heme oxygenase-1 (H-
O-1) forward, CAGGCAGAGAATGCTGAGTTC; HO-1 reverse,
GATCTTGAGCAGGAACGCAGT.
Western Blot Analysis—Cells were lysed in a buffer containing 100
mM NaCl, 10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 1 mM phenylmethyl-
sulfonyl fluoride, and 1% Nonidet P-40. Protein concentration in cell
lysates was determined using a commercial protein assay kit (Bio-Rad).
After adding a loading buffer containing 50 mM Tris-HCl, pH 6.8, 2%
SDS, 8% glycerol, and 0.4% -mercaptoethanol, an equal amount of
protein for each sample was separated by 12% SDS-PAGE and trans-
ferred to Hybond enhanced chemiluminescence (ECL) membranes (Am-
ersham Biosciences). After incubation in 1:1,000 dilution of primary
antibodies to MnSOD (Calbiochem), Cu,Zn-SOD(Upstate USA Inc.,
Charlottesville, VA) or cGPx (Labfrontier Co., Seoul, Korea), mem-
branes were probed with appropriate horseradish peroxidase-conju-
gated secondary antibody (Amersham Biosciences). Bound antibody
was visualized using an ECL reagent (Amersham Biosciences).
Measurement of Cell Death—After treatment of cells with 25 to 75
mM menadione (Sigma), 1 to 20 mM paraquat (Sigma), 50 to 100 mM
H2O2 (Sigma), 100 to 200 nM doxorubicin (Donga Pharmaceuticals,
Seoul, Korea), or infection with Avpp53 (15), the trypan blue exclusion
test was performed by incubating cells in 0.02% trypan blue solution
(Invitrogen) for 5 min. Avpp53 and Ad5CMVSOD2 (Gene Transfer
Vector Core, University of Iowa, Iowa City, IA) were propagated in HEK
293 cells and concentrated by the standard CsCl ultracentrifugation
method. Cells seeded on 96-well plates were infected with Avpp53 at a
multiplicity of infection of 50 in a serum-free medium for 1 h. For
multiple adenoviral transduction, Ad5CMVSOD2 infection at a multi-
plicity of infection of 50–100 was performed 24 h before Avpp53 infec-
tion. For some experiments, preincubation with 1 mM N-acetylcysteine
(Sigma) or 1 mM reduced GSH (Sigma) for 30 min or with Zn(II)
protoporphyrin IX (ZnPP, Frontier Scientific Inc., Logan, UT) for 24 h
was done before treatment with test reagents.
ROS Measurement—For intracellular superoxide anion (O2
.) meas-
urement, cells were incubated with 1 g/ml fresh dihydroethidium
(Molecular Probes, Eugene, OR) in Hanks’ balanced salt solution at
37 °C for 15 min. Flow cytometry was conducted after washing in
Hanks’ balanced salt solution (excitation, 518 nm; emission, 605 nm). In
the case of intracellular H2O2, cells were incubated with 10 g/ml fresh
2,7-dichlorofluorescein diacetate (Molecular Probes) in Hanks’ bal-
anced salt solution at 37 °C for 30 min for flow cytometry (excitation,
485 nm; emission, 530 nm).
GPx Activity—cGPx activity was measured using a published proto-
col with modifications (16). In short, postnuclear fractions were pre-
pared by douncing cells in an isotonic buffer (10 mM HEPES, pH 8.0,
250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 2 mM
phenylmethylsulfonyl fluoride, and 100 g/ml leupeptin) and spinning
down at 800  g. Supernatant comprising both mitochondrial and
cytoplasmic fraction was sonicated in a Branson sonifier 450 (Danbury,
CT) and saved for measurement of enzymatic activity. Appropriately
diluted protein samples were added to 700 l of the reaction mixture
containing 50 mM Tris-HCl, pH 7.6, 5 mM EDTA, 1 mM GSH, 0.2 mM
NADPH, and 0.5 unit of glutathione reductase (Calbiochem, La Jolla,
CA). The reaction was started by adding 350 l of 0.22 mM t-butyl
hydroperoxide as a substrate at 25 °C. The decrease in absorbance at
340 nm was monitored by a UV spectrophotometer for conversion to the
enzyme activity. The rate of the decrease in A340 was converted to the
activity using the following formula: 1 milliunit/ml 1 nmol of NADPH/
min/ml  A340/min/0.00622.
Electrophoretic Mobility Shift Assay—Nuclear extracts were pre-
pared as previously described (17). Synthetic double-stranded oligonu-
cleotides of the consensus NF-B binding sequence, AGTTGAGGG-
GACTTTCCCAGGC (Promega), were end-labeled with [-32P]ATP
using T4 polynucleotide kinase. Nuclear extract was incubated with the
labeled probe in the presence of poly(dI-dC) in a binding buffer contain-
ing 20 mM HEPES at room temperature for 30 min. DNA-protein
complexes were resolved by electrophoresis in a 5% non-denaturing
polyacrylamide gel and visualized by autoradiography.
RESULTS
Increased MnSOD Expression in SK-Hep1 0 Cells—First, we
studied the changes of gene expression in SK-Hep1 0 cells
FIG. 1. Markedly increased expression of MnSOD in SK-Hep1
0 cells. A, RT-PCR analysis showed profoundly increased expression of
MnSOD compared with parental cells at the RNA level, whereas the
expression of Cu,Zn-SOD and a control gene (glyceraldehyde-3-phos-
phate dehydrogenase, GAPDH) was not different between the two cells.
B, Western blot analysis confirmed the increased MnSOD in 0 cells at
the protein level. The expression of Cu,Zn-SOD was not different be-
tween the two cells.
FIG. 2. Increased ROS production
by EtBr treatment of parental cells.
A, flow cytometric analysis after dihydro-
ethidium (HE) loading showed that EtBr
treatment for 10 days resulted in a
marked increase in O2
. contents compared
with untreated parental cells. B, contents
of H2O2 stained by 2,7-dichlorofluores-
cein diacetate (DCFH-DA) were not
changed by the same treatment. C, O2
.
contents in fully established SK-Hep1 0
cells cultured with EtBr for more than 2
years were not different from that in pa-
rental cells.
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using DNA chip analysis (Genomic Tree, Taejon, Korea).
Among the genes that were overexpressed in SK-Hep1 0 cells,
MnSOD was one of the genes that showed the most striking
increase in the expression levels compared with parental cells
(-fold increase of 20.9). The increased expression of MnSOD in
SK-Hep1 0 cells was confirmed by RT-PCR and Western blot
analysis (Fig. 1, A and B). In contrast to MnSOD that is
expressed in mitochondria and metabolizes O2
. produced during
mitochondrial electron transfer, the expression of Cu,Zn-SOD,
another major superoxide dismutase expressed in cytoplasm
was not changed as demonstrated by RT-PCR and Western blot
analysis (Fig. 1, A and B).
Increased ROS Production during 0 Cell Derivation but Not
in Established 0 Cells—The increased expression of MnSOD
could be an adaptive response to the failure of mitochondrial
electron transport and an increase in the leakage of O2
. from
mitochondria of SK-Hep1 0 cells (18). As SK-Hep1 0 cells
might be in a new equilibrium between increased O2
. produc-
tion and increased MnSOD expression, they might not be good
models to study the changes in ROS contents by the interrup-
tion of mitochondrial electron transfer (see Fig. 2C). Thus, we
reiterated the derivation of mtDNA-depleted SK-Hep1 0 cells
by culturing parental cells with 100 ng/ml EtBr and studied if
the blockade of the mitochondrial electron transfer by the in-
hibition of mtDNA replication with EtBr leads to an increased
intracellular ROS. As hypothesized, intracellular O2
. contents
measured by dihydroethidium were increased after incubation
of parental cells with EtBr for 10 days compared with un-
treated cells (Fig. 2A), suggesting that the inhibition of mito-
chondrial respiratory complexes blocks mitochondrial electron
transport between mitochondrial respiratory complexes and en-
hances the production of O2
. (18). Intracellular H2O2 measured by
2,7-dichlorofluorescein diacetate was not increased by SK-Hep1
parental cell treatment with EtBr probably because the compen-
satory increase in MnSOD and the adaptive increase in the
dismutation of O2
. to H2O2 had not yet occurred after 10 days of
treatment (Fig. 2B). O2
. contents in fully established SK-Hep1 0
cells that have been maintained for more than 2 years was not
different from that in parental cells probably because of the
equilibrium between the increased O2
. production and increased
O
2
. dismutation (Fig. 2C).
Resistance of SK-Hep1 0 Cells against ROS—Next, we stud-
ied if SK-Hep1 0 cells were resistant to ROS by metabolizing
ROS efficiently because of the increased expression of MnSOD.
We first treated SK-Hep1 0 cells and parental cells with men-
adione, a prototypic oxygen stressor of the quinonoid type pro-
ducing O2
. (19, 20). We employed a trypan blue exclusion assay
as a measure of cell death because ROS induces cell death of
mixed patterns showing both necrosis and apoptosis depending
on the experimental condition and differentiation between ne-
crosis, and apoptosis on the morphological ground does not
have much significance when the death effector is already
known as ROS (21, 22). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assay was not employed because such
assay testing of mitochondrial succinate dehydrogenase activ-
ity was not considered appropriate when studying cells with
mtDNA depletion. Treatment with 25–75 M menadione for
24 h induced death of SK-Hep1 parental cells in a dose-depend-
ent manner. In contrast, SK-Hep1 0 cells were resistant to
treatment with menadione (Fig. 3A). Because these results
suggested the possibility that SK-Hep1 0 cells acquired resist-
ance to menadione by metabolizing O2
. more rapidly because of
the increased MnSOD, we next measured the intracellular O2
.
contents after treatment with menadione. As hypothesized,
intracellular O2
. contents after treatment of SK-Hep1 0 cells
with 1 mM menadione for 20 min were significantly lower than
that after the same treatment of parental cells (Fig. 3B). O2
.
contents before menadione treatment was not different be-
tween the two cells probably because of the equilibrium be-
tween the increases in O2
. production and that in disposal (Fig.
2C). Contents of H2O2 after menadione treatment that is pro-
duced from O2
. by SOD were not significantly different between
SK-Hep1 0 cells and parental cells (Fig. 3C), suggesting a new
equilibrium between the increased dismutation of O2
. and an
increased processing of H2O2 in SK-Hep1 
0 cells (see Figs. 5
and 6).
We then studied the effect of another oxidative stressor pro-
ducing superoxide, paraquat (23, 24). Treatment with 1–20 mM
paraquat induced death of SK-Hep1 parental cells in a dose-
dependent manner; however, SK-Hep1 0 cell death after para-
quat treatment was markedly less compared with parental
cells (Fig. 4A). Similar to the menadione treatment, intracellu-
lar O2
. contents after treatment of SK-Hep1 0 cells with 10 mM
paraquat were lower than that after the same treatment of
parental cells, which is consistent with our hypothesis that
SK-Hep1 0 cells are able to metabolize O2
. more rapidly by
increased MnSOD and acquired resistance to O2
. (Fig. 4B).
H2O2 contents after paraquat treatment were not significantly
different between SK-Hep1 0 cells and parental cells, similar
to menadione treatment (Fig. 4C).
Next we studied the expression of H2O2 metabolizing en-
FIG. 3. Resistance of SK-Hep1 0 cells against menadione. A,
Trypan blue staining showed that 0 cells were resistant to menadione,
an ROS stressor producing O2
. (mean  S.D.). B, intracellular O2
. con-
tents after menadione treatment were lower in 0 cells compared with
parental cells. C, intracellular H2O2 contents after menadione treat-
ment were not different between the two cells. HE, dihydroethidium;
DCFH-DA, 2,7-dichlorofluorescein diacetate.
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zymes and the susceptibility of SK-Hep1 0 cells to H2O2 be-
cause SK-Hep1 0 cells may need to process increased intracel-
lular H2O2 by MnSOD overexpression. We studied the
expression of GPx that catalyzes the conversion of H2O2 to H2O
and O2 in various compartments of the cells including mito-
chondria (25). RT-PCR analysis showed that the expression of
2 types of GPx (cGPx and PHGPx) that are expressed in mito-
chondria (25) was increased in SK-Hep1 0 cells compared with
parental cells (Fig. 5A). In contrast, the expression of catalase
that metabolizes H2O2 in peroxisome was not increased (Fig.
5A). Western blot analysis also demonstrated that the ex-
pression of the cGPx protein was increased in SK-Hep1 0
cells (Fig. 5B). The increased cGPx expression was functional
because cGPx activity in the postnuclear fraction of SK-Hep1
0 cells comprising both cytoplasmic and mitochondrial frac-
tions was significantly increased compared with parental
cells (Fig. 5C).
To directly prove that SK-Hep1 0 cells have an increased
ability to process H2O2, we studied susceptibility of SK-Hep1 
0
cells to exogenous H2O2 that readily permeates across biologi-
cal membranes (26). Similar to other oxidative stressors, 50–
100 M H2O2 induced SK-Hep1 parental cell death in a dose-
dependent manner. However, SK-Hep1 0 cells were markedly
resistant to H2O2, suggesting a more rapid disposal of exoge-
nous H2O2 by the increased GPx expression (Fig. 6A). Intracel-
lular H2O2 contents after H2O2 treatment were also lower in
SK-Hep1 0 cells compared with parental cells (Fig. 6B), which
is consistent with our hypothesis that SK-Hep1 0 cells ac-
quired resistance to H2O2 by the increased expression of cGPx
or PHGPx. H2O2 contents before H2O2 treatment were not
different between the two cells (Fig. 6C).
Resistance of SK-Hep1 0 Cells to p53—Next we studied the
possible resistance of SK-Hep1 0 cells against p53 because
several previous reports indicated the role of ROS in p53-
induced apoptosis (27–29). SK-Hep1 cell death after infection
with adenovirus expressing p53 (Avpp53) was dependent upon
ROS because antioxidants such as N-acetylcysteine or GSH
inhibited p53-induced SK-Hep1 parental cell death (Fig. 7A).
Trypan blue exclusion assay showed that SK-Hep1 0 cells were
markedly resistant to adenoviral transduction of p53, consistent
with our hypothesis (Fig. 7B). Both intracellular O2
. and H2O2
contents in SK-Hep1 parental cells were increased after adeno-
viral expression of p53, consistent with the inhibition of p53-
induced SK-Hep1 cell death by antioxidants (Fig. 7C). Intracel-
lular O2
. and H2O2 contents after adenoviral expression of p53 in
SK-Hep1 0 cells were not apparently different from that before
infection, suggesting that the increased expression of MnSOD
FIG. 4. Resistance of SK-Hep1 0 cells against paraquat. A, 0
cells were resistant to paraquat (mean  S.D.). B, O2
. contents after
paraquat treatment were lower in 0 cells compared with parental
cells. C, H2O2 contents after paraquat treatment were not different
between the two cells. HE, dihydroethidium; DCFH-DA, 2,7-dichlo-
rofluorescein diacetate. FIG. 5. Increased GPx expression in SK-Hep1 0 cells. A, RT-
PCR analysis showed that the expression of cGPx and PHGPx was
increased in 0 cells compared with parental cells at the RNA level,
whereas the expression of catalase was not different between the two
cells. B, immunoblot analysis showed that cGPx protein expression was
increased in 0 cells. C, cGPx activity was also increased in 0 cells
compared with parental cells (mean  S.D.). GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
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and GPx protected SK-Hep1 0 cells from p53-induced death
by attenuating ROS production (Fig. 7C). In addition to p53,
SK-Hep1 0 cells were resistant to doxorubicin that induces
target cell death by multiple mechanisms including DNA
breakage, p53 induction (30, 31), and ROS production (32, 33)
(Fig. 7D).
Protection of Parental Cells by MnSOD Overexpression—To
directly prove the role of MnSOD in the resistance against ROS
or p53, we infected parental cells with adenovirus expressing
MnSOD (Ad5CMVSOD2). MnSOD expression was strongly in-
duced by infection with Ad5CMVSOD2 (Fig. 8A). Adenoviral
overexpression of MnSOD partly but significantly reduced tar-
get cell death by menadione, paraquat, adenoviral p53 expres-
sion, and doxorubicin, suggesting that the increased dismuta-
tion of O2
. by adenoviral MnSOD expression decreased cell
death by ROS donors or p53. However, SK-Hep1 cell death by
H2O2 that occurs downstream of MnSOD was not decreased by
adenoviral expression of MnSOD (Fig. 8B).
Resistance of Other Types of 0 Cells against ROS—To inves-
tigate if the increased expression of MnSOD and the resistance
against ROS are restricted to a specific type of 0 cells (SK-
Hep1 0 cells) or relevant to other types of 0 cells, we examined
the expression of MnSOD in MIN6N8 0 cells and MDA-MB-
435 0 cells. Both cells had increased expression of MnSOD
compared with their respective parental cells and showed re-
sistance against menadione (Fig. 9, A and B), paraquat, or
doxorubicin (data not shown), suggesting that the induction of
MnSOD and the resistance against ROS are general phenom-
ena common to a wide variety of 0 cells.
Role of HO-1 in MnSOD Induction—To address the mecha-
nism of antioxidant enzyme induction in 0 cells, we studied the
possible activation of NF-B that is reportedly activated by
ROS and induces MnSOD expression. However, our electro-
phoretic mobility shift assay analysis clearly showed that
NF-B was not activated in untreated SK-Hep1 0 cells,
whereas treatment with 10 ng/ml tumor necrosis factor  for 15
min induced strong NF-B activation in SK-Hep1 0 cells as
well as parental cells (Fig. 10A). We next studied the role of
HO-1 whose expression was increased more than 4-fold in our
DNA chip analysis and which has been reported to induce
MnSOD in response to oxidative stress (34, 35). A strong in-
duction of HO-1 in SK-Hep1 0 cells was confirmed by RT-PCR
analysis (Fig. 10B). Treatment with the HO-1 inhibitor ZnPP
for 24 h decreased the expression of MnSOD and cGPx at RNA
and protein levels in a dose-dependent manner (Fig. 10, C and
D). Pretreatment of SK-Hep1 0 cells with ZnPP for 24 h also
markedly attenuated the resistance of SK-Hep1 0 cells against
menadione, doxorubicin, paraquat, adenoviral p53 infection,
and H2O2, strongly indicating the role of HO-1 in the induction
of antioxidant enzymes in SK-Hep1 0 cells and their resistance
against ROS (Fig. 10E).
DISCUSSION
In our DNA chip analysis to elucidate the mechanism of cell
survival without mitochondrial oxidative phosphorylation and
their resistance against various cell death modes, we observed
a striking elevation of MnSOD expression in mtDNA-depleted
SK-Hep1 0 cells but no change in Cu,Zn-SOD expression. This
observation is consistent with previous papers showing an Mn-
SOD expression in tissues from patients with various types of
mtDNA mutation/deletion (36, 37) and those reporting the
ability of MnSOD to suppress several types of cell death (38,
39). Besides SK-Hep1 0 cells, we also observed the increased
expression of MnSOD in other types of 0 cells. The increased
expression of MnSOD in various types of 0 cells and in the
tissues with mitochondrial dysfunction is most likely an adapt-
ive process to the overproduction of ROS. Increased ROS pro-
duction in cells or tissues with mitochondrial mutations or
dysfunction has been shown (36, 40), which is probably because
of the blockade of mitochondrial electron transfer within or
between mitochondrial respiratory complexes and subsequent
leakage of electrons as O2
.. We observed no increase of basal
ROS levels in SK-Hep1 0 cells, which might represent a new
equilibrium between the overproduction of ROS and the induc-
tion of MnSOD. As we could not demonstrate the increased
ROS levels in 0 cells, we had to repeat EtBr treatment of
parental cells again to prove that the blockade of mitochondrial
electron transfer increases ROS production. As a 10-day period
of EtBr treatment was long enough to inhibit transcription/
replication of mitochondrial DNA but not long enough for the
development of cell clones with the adaptive MnSOD overex-
pression, we were able to demonstrate the increase in O2
. pro-
duction before reaching a new equilibrium. Intracellular H2O2
contents were not increased after 10 days of EtBr treatment
probably because MnSOD overexpression and increased dismu-
tation of O2
. to H2O2 had not yet occurred.
We reasoned that the increased MnSOD expression in SK-
Hep1 0 cells would affect the intracellular metabolism of ex-
ogenous ROS and the outcome of the cells after treatment with
ROS donors. Consistent with our hypothesis, SK-Hep1 0 cells
showed remarkable resistance to menadione and paraquat,
both of which produce superoxide anion through redox cycles
(19, 23). Much less intracellular O2
. levels were also observed
after treatment of SK-Hep1 0 cells with menadione or para-
quat, suggesting an increased dismutation of intracellular O2
..
However, increased dismutation of O2
. may not necessarily
confer a beneficial effect on host cells because of the increased
FIG. 6. Resistance of SK-Hep1 0 cells against H2O2. A, SK-Hep1
0 cells were resistant to exogenous H2O2 (mean  S.D.). B, H2O2
contents after H2O2 treatment were lower in SK-Hep1 
0 cells compared
with parental cells. C, H2O2 contents before H2O2 treatment were not
different between the two cells. HE, dihydroethidium; DCFH-DA, 2,7-
dichlorofluorescein diacetate.
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generation of other ROS such as to H2O2 (41). Thus, the resist-
ance of SK-Hep1 0 cells against menadione or paraquat may
be due not only to the overexpression of MnSOD but to the
overexpression of GPx. Whereas the -fold increase of GPx ex-
pression was less than that of MnSOD, it was functional as
shown in our assay of GPx enzyme activity. Furthermore, SK-
Hep1 0 cells were markedly resistant to exogenous H2O2, and
intracellular H2O2 levels after H2O2 treatment were less com-
pared with parental cells, consistent with the increased GPx
expression. We observed up-regulation of 2 forms of GPx (cGPx
and PHGPx) that are expressed in both mitochondria and
cytoplasm (25, 42). As H2O2 readily moves across intracellular
compartments, both cytoplasmic and mitochondrial forms of
GPx would participate in the metabolism of H2O2.
In addition to the resistance to ROS donors, SK-Hep1 0 cells
showed marked resistance to p53-induced death, which consti-
tutes one of the most important host surveillance against can-
cers. Consistent with our results, MnSOD overexpression has
been reported to inhibit p53-induced death (39). Multiple mech-
anisms have been proposed for p53-induced apoptosis (43), and
ROS has been reported as an important downstream effector of
p53 (27–29). In our model also, p53-induced cell death was
dependent on ROS as it was inhibited by antioxidants. Because
SK-Hep1 cell death by p53 was dependent on ROS, we could
test if SK-Hep1 0 cells were resistant to p53-induced apoptosis
and indeed they were consistent with previous reports by oth-
ers (29). Adenoviral p53 expression in SK-Hep1 0 cells also did
not increase O2
. or H2O2 contents, suggesting that the increased
expression of both MnSOD and GPx is involved in the resist-
ance of SK-Hep1 0 cells against p53. These results suggest an
intriguing possibility that various cancers with frequent
FIG. 8. Effect of MnSOD overexpression on cell death. A, strong
MnSOD expression was observed by Western blot analysis after infec-
tion of parental cells with adenovirus expressing MnSOD. B, adenoviral
MnSOD expression partially inhibited SK-Hep1 cell death by menadi-
one, paraquat, doxorubicin, and p53 adenoviral expression but not by
exogenous H2O2 (mean  S.D.).
FIG. 7. Resistance of SK-Hep1 0 cells against p53 (mean  S.D.). A, death of SK-Hep1 parental cells by adenoviral p53 expression was
inhibited by GSH or N-acetylcysteine (NAC). B, SK-Hep1 0 cells were resistant to adenoviral expression of p53. C, intracellular contents of O2
. or
H2O2 after adenoviral p53 expression were lower in SK-Hep1 
0 cells compared with parental cells (% of control fluorescence). D, SK-Hep1 0 cells
were resistant to doxorubicin that induces cell death in part through p53 activation. DCFH-DA, 2,7-dichlorofluorescein diacetate.
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mtDNA mutations (8, 9) avoid host anti-cancer surveillance
imposed by p53, whereas the complete depletion of mtDNA in
0 cells will not be comparable with the effect of multiple
deletions in mtDNA of cancer cells.
The resistance of SK-Hep1 0 cells against doxorubicin is
consistent with a previous report using HeLa 0 cells (44) and
might be explained by the combined effect of the resistance
against p53 and that against ROS, the two main but not mu-
FIG. 9. Increased expression of Mn-
SOD in other types of 0 cells. Both
MIN6N8 0 cells of an insulinoma cell or-
igin (A) and MDA-MB-435 0 cells of a
breast cancer cell origin (B) showed in-
creased MnSOD expression. They were
also resistant to menadione, like SK-
Hep1 0 cells.
FIG. 10. Role of HO-1 in MnSOD in-
duction. A, NF-B was not activated in
untreated SK-Hep1 0 cells, whereas tu-
mor necrosis factor  treatment for 15
min induced strong NF-B activation in
both parental cells and 0 cells. B, RT-
PCR analysis showed that HO-1 was up-
regulated in SK-Hep1 0 cells. Treatment
of SK-Hep1 0 cells with ZnPP, an HO-1
inhibitor, markedly decreased the expres-
sion of MnSOD and cGPx at RNA (C) and
protein levels (D). E, ZnPP also attenu-
ated the resistance of SK-Hep1 0 cells
against menadione, paraquat, doxorubi-
cin, p53, and H2O2.
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tually exclusive mechanisms of doxorubicin effect (30–32). This
result suggests the possibility that the mtDNA mutation ob-
served in cancers is one of the important causes of the resist-
ance against chemotherapeutics frequently observed in ad-
vanced cancers.
Aged cells or cancer cells have increased frequency of
mtDNA mutation/deletion. The percentage of individual muta-
tion/deletion may be low in aged cells but the total frequency of
various kinds of mutations/deletions including known and un-
known ones may be high (10, 11). Several specific mutations
have been reported to occur up to 50% in aged fibroblasts (11).
Mitochondrial abnormalities were also found in almost 80% of
some types of cancers (8, 9). A significant proportion of those
aged cells or cancer cells with mitochondrial abnormalities
would have increased intracellular ROS contents. Most of such
cells will be dead because of the increased ROS; however, some
of them will adapt to the increased ROS production by inducing
antioxidant enzymes. Once survived, such cells would have a
survival advantage over normal cells with intact mitochondrial
function because they may be able to endure endogenous or
exogenous oxidative stress and avoid cancer surveillance by
p53 or TRAIL (7). This suggestion is consistent with previous
papers showing increased MnSOD and GPx expression in
aged or senescent tissue (45–47) and also a recent paper
showing the decreased apoptosis of aged cells to genotoxic
stress (48). In cancer cells, most previous reports (49, 50)
showed low MnSOD expression. However, several recent pa-
pers (51–53) reported an increased expression of MnSOD in
advanced cancer tissue, particularly in relation to poor prog-
nosis or metastasis. Most cancer tissues might not have an
increased expression of antioxidant enzymes; however, some
selected cancer cells might have an increased expression of
antioxidant enzymes leading to resistance against exogenous
stress and poor prognosis (54).
Regarding the molecular mechanism of MnSOD induction in
0 cells, NF-B does not appear to play a role. Whereas NF-B is
one of the most extensively studied among the known inducers of
MnSOD and has been reported to be activated by ROS (55, 56),
we could clearly demonstrate that NF-B was not activated in
untreated SK-Hep1 0 cells. A recent paper demonstrated that
ROS itself does not mediate NF-B activation (57), contrary to
previous reports. Our observation that HO-1 was markedly over-
expressed in SK-Hep1 0 cells and that ZnPP as an HO-1 inhib-
itor decreased the expression of MnSOD/cGPx and also the re-
sistance of SK-Hep1 0 cells against various ROS donors strongly
suggests that HO-1 is an important mediator of the induction of
MnSOD and cGPx in SK-Hep1 0 cells. These results are consist-
ent with previous reports that HO-1 is rapidly induced by various
pro-oxidants and serves to normalize the redox microenviron-
ment by catabolizing pro-oxidant metalloporphyrins to bile pig-
ment and also by inducing antioxidant enzymes such as MnSOD
(35, 58). Whereas our results suggest a mechanism of the induc-
tion of antioxidant enzymes in response to ROS, further studies
will be necessary to understand the biological significance and
detailed biochemical mechanism of these observations and to
extrapolate these findings from artificial 0 cells to the resistance
of natural senescent cells or cancer cells against various types of
cell death.
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